Sumitomo Chemical India LtdNSE: SUMICHEM
Open the Sumitomo Chemical India Ltd page
Follow Sumitomo Chemical India LtdFree account. Get a note when Sumitomo Chemical India Ltd files.
Q4 FY26 results analysis · May 26, 2026

Sumitomo Chemical India Ltd Q4 FY26 Results Analysis: EBITDA Margin Hits 20.72%, Debt-Free Balance Sheet

+11.6%PAT year on year, Rs. 111.32 Cr
Cofacto ResearchPublished May 26, 20262 min readNeutral read
Quick summary

Sumitomo Chemical India Ltd's Q4 FY26 numbers came in mixed, with revenue of Rs. 683.74 Cr (+0.60% YoY) and PAT growth of +11.60% YoY. Here's a quick read of what worked, what to watch, and what management said.

Quick Details
Results dateMay 26, 2026
QuarterQ4 FY 2025-2026
Revenue (Q4)Rs. 683.74 Cr (+0.60% YoY)
PAT (Q4)Rs. 111.32 Cr (+11.60% YoY)
EBITDA margin20.72% (+65 bps YoY)
EPS (Q4)Rs. 2.23 (+11.50% YoY)
Market capRs. 23,449.78 Cr
CMPRs. 469.60

Quarter Snapshot

Sumichem delivered on margin targets (20.72% EBITDA margin vs >20% target) but revenue growth was muted at +2.9% as pricing pressure offset volume gains. A debt-free balance sheet with Rs.1,221 Cr liquidity provides resilience, but working capital absorption and unresolved glyphosate regulation are near-term overhangs. The company's strong domestic and export volume growth suggests underlying demand is intact, with pricing stabilization being the key catalyst to watch.

Key Investment Insights

Key Positives

  • Q4 FY26 revenue of Rs.6,837 Mn rebounded +20.4% QoQ after a weak Q3
  • FY26 EBITDA margin of 20.72% exceeded management's >20% target
  • PAT grew +11.6% YoY in Q4 FY26 to Rs.1,113 Mn
  • Balance sheet is debt-free with Rs.1,221 Cr in cash and investments
  • Trade receivables declined 6.1% YoY indicating improved collections
  • Normalized FY26 PAT growth (adjusted for exceptional labour code charge) was +9.6% YoY

Risk Factors

  • Revenue growth was just +2.9% for FY26 as pricing pressure (~17-18% realization decline) offset volume growth of 25%+
  • Glyphosate regulatory overhang remains unresolved
  • Capex of Rs.442 Mn was only 44% of the 15%-of-EBITDA target of Rs.1,006 Mn
  • Net working capital absorbed Rs.71 Cr as inventories grew 8.9% and payables declined 18.8%

Ask about this

Ask Cofacto a question about this result. Answers cite filings and company data.

Companies on this page
Share on X · LinkedIn · WhatsApp

Disclaimer: This results analysis is published for educational and informational purposes only. It is not investment advice, not a recommendation to buy, sell or hold any security.